ForteBio
ForteBio, a subsidiary of Sartorius AG, operates in the life sciences sector, specializing in bioprocess solutions and lab products.
Profile
Provides analytical instruments and consumables for biopharmaceutical research and production.
ForteBio, a subsidiary of Sartorius AG, operates in the life sciences sector, specializing in bioprocess solutions and lab products. Originally founded as an independent company, ForteBio was acquired by Sartorius, a global leader in biopharmaceutical equipment and services, to bolster its biolayer interferometry and analytical capabilities. The company's product portfolio includes advanced technologies for bioprocess monitoring, protein analysis, and cell culture, serving pharmaceutical and biotechnology firms.
ForteBio's financial trajectory shows resilience, with Sartorius reporting Q1 2026 Group sales revenue growth of 7.5% to €899 million, driven by strong consumables demand. The Bioprocess Solutions Division, which includes ForteBio's offerings, grew 8.1% in the same period. Sartorius employs 14,242 people globally, with ongoing investments in capacity expansion.
Recent focus includes scaling cell and gene therapy solutions, evidenced by a new competence center in Freiburg, Germany. The company's integration into Sartorius provides stability but also ties its performance to the parent company's broader strategic shifts.
Who buys this
- Pharmaceutical companies developing biologics
- Biotechnology firms focused on cell and gene therapies
- Academic and government research laboratories
- Contract research and manufacturing organizations (CROs/CMOs)
Strengths and what to watch
Strengths
- Integrated into Sartorius' global bioprocess infrastructure, ensuring supply chain stability
- Specialized biolayer interferometry technology for real-time protein analysis
- Recurring revenue from consumables, which drove 2026 Q1 growth
Watch for
- Dependence on Sartorius' corporate strategy and potential R&D prioritization shifts
- Geopolitical and tariff impacts on equipment sales, noted in Q1 2026 earnings
- Competition from standalone biolayer interferometry providers like Pall FortéBio (unrelated entity)
Recent moves
Key Information
- Founded
- 1870
- Employees
- 14242
- Headquarters
- Göttingen, Germany. It
Frequently Asked Questions
What does ForteBio do?
ForteBio provides analytical instruments and consumables for biopharmaceutical research and production. Specializing in bioprocess solutions and lab products, it offers advanced technologies for protein analysis, bioprocess monitoring, and cell culture, serving pharmaceutical and biotechnology firms.
What is biolayer interferometry?
Biolayer interferometry is a technology developed by ForteBio for real-time protein analysis. It enables precise monitoring of molecular interactions, making it essential for biopharmaceutical research and development processes.
How is ForteBio connected to Sartorius AG?
ForteBio is a subsidiary of Sartorius AG, a global leader in biopharmaceutical equipment and services. The acquisition bolstered Sartorius' capabilities in biolayer interferometry and analytical technologies, integrating ForteBio into its bioprocess infrastructure.
What industries does ForteBio serve?
ForteBio serves pharmaceutical companies developing biologics, biotechnology firms focused on cell and gene therapies, academic and government research laboratories, and contract research and manufacturing organizations (CROs/CMOs).
How has ForteBio performed financially?
ForteBio's financial performance shows resilience, with Sartorius reporting Q1 2026 Group sales revenue growth of 7.5% to €899 million. The Bioprocess Solutions Division, which includes ForteBio, grew 8.1%, driven by strong consumables demand.
What are ForteBio's recent developments?
ForteBio is scaling cell and gene therapy solutions, evidenced by Sartorius' new competence center in Freiburg, Germany. This focus aligns with the growing demand for advanced therapies in the biopharmaceutical industry.
Sources
- www.sartorius.com — Q1 2026 financial performance and headcount
- www.sartorius.com — Cell and gene therapy center launch
- www.sartorius.com — Product offering details
- www.sartorius.com — Cubis® III product details